RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing led a $120m in IDRx.

RA Capital Management, a multi-stage investment manager, Commodore Capital, an early stage investor, and Blackstone Multi-Asset Investing, a multi-asset investor, led a $120m in IDRx, a clinical-stage biopharmaceutical company, with participation from Rock Springs Capital, Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Merck. “RA Capital Management is excited to co-lead this round to support the advancement of IDRX-42 as a differentiated new treatment for GIST. We have been extremely impressed by what the IDRx team has accomplished in a short time, and I look forward to contributing to IDRx’s future growth and success as the company prepares to execute on its late-stage clinical development activities for IDRX-42,” Derek DiRocco, RA Capital Management Partner.